Cotinga Pharmaceuticals Inc.
Share · CA22164W1059 (OTC)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Cotinga Pharmaceuticals Inc.
No Price
Company Profile for Cotinga Pharmaceuticals Inc. Share
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Company Data
Name Cotinga Pharmaceuticals Inc.
Company Cotinga Pharmaceuticals Inc.
Website
https://www.cotingapharma.com
Primary Exchange 
UTC
UTC
ISIN CA22164W1059
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Richard T. Ho
Country Canada
Currency USD
Employees -
Address The Canadian Venture Building, M5C 1P1 Toronto
IPO Date 2009-09-28
Stock Splits
| Date | Split |
|---|---|
| 30.06.2017 | 1:10 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | COTQF |
More Shares
Investors who hold Cotinga Pharmaceuticals Inc. also have the following shares in their portfolio:
